Drug Approval Process Flashcards

1
Q

How does the approval of cancer drugs differ from other types of drugs?

A
  • They can be approved on the basis of Surrogate end products (made up goals)
  • They don’t have to cure cancer they just have to stop it
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Why might data for the side effects of drugs be incomplete?

A
  • Average amount of time used to determine drug side effects is 6 months so you don’t get an idea of the long term side effects of taking a drug
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What kind of patients are used in phase I clinical trials?

A

Phase I trials

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

T or F: many trials don’t compare the drug to a gold standard and just use a placebo instead

A

True, they don’t want you to know that the new drug is worse than the old drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is an orphan drug?

A

Drug that would be used by so few patients that is would never be made if it weren’t for FDA help (incentive)

**Any drug for a target of less than 200,000 ppl

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

T or F: OTCs reduce cost, but the cost then shifts from the HMO to the consumer.

A

True

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What Milestones in drug regulation were met in:

  • 1906
  • 1938
  • 1962
A

1906:
- Drugs were no longer allowed to be mislabed or adulterated (PURITY was the goal)

1938:
- Required SAFETY in addition to Purity

1962:
- Drugs need to be EFFECTIVE, SAFE, and PURE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What group of drugs is approved solely on the basis of animal testing?

A

Anti-Bioterrism Drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Why should you be very cautious about prescribing a new drug?

A

1/5 of approved drugs will be pulled from the market due to toxicity issues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the 4 general phases of making a drug?

A

In vitro studies (0-2 years):
- A library of similar compounds is made and tested

Animal Testing (2-4 years): 
- Efficacy Selectivity we just want to see if it works in animals 
Clinical Testing (4-8 years): 
- Clinical Testing (phase 0 - phase 3) 

Marketing:
- Phase 4 “trials”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

After what phase can drugs fill out their new drug application?

A

After clinical Testing - this takes 8-9 years to get to this point meaning it only has 11-12 years left before generics can compete.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What happens during phase 0 of the clinical trials?

A

Drugs in this day and age have a defined target and we want to see how well it hits that target

**Measure relationship between dose and target

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How many chemical entries are submitted to get 1 drug candidate?
- what are the variations exist among these entries?

A

5,000 to 10,000 entries to get one drug

  • Change pks, metabolism, solubility, route of delivery etc.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Before moving to human trials what is the goal?

A
  • Keep it simple and cheap
  • Use less animals
  • Keep the amount of drug that needs to be synthesized down to a minimum
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the difference for 1st in class drugs and Follower drugs as far as targeting to specific receptors goes?

A

First in Class drugs:
- we look more at outcome - is the patient getting corrected to the right phenotype

Follower Drugs:
- We start looking at How well the Drug is binding to the RECEPTOR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How have drug companies changed their minds about potency and efficacy?
- what do they now do to ensure drugs work?

A

Old Way:
- Make a compound with the highest potency and wait until off on animal trials to look at pharacokinetics

New Way:
- Use RAPID ADME-TOX assays to assess solubility, Absoption (artificial membranes), and Metabolism (Hepatocytes or Microsomes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

How can we look at how much a molecule will interfere with CYPs without using an animal?

A

Put 3-5 compounds on an HPLC column loaded with CYP proteins to see what drugs interact most strongly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are Herg Channels?

- how do we test for interactions here?

A

Herg Channels are the K+ channels of the Heart

  • Terfenadine was a drug put on the market before this testing was done and had to be pulled back off (Costed the company tons of money)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the general trend if you’re trying to determine any sort of toxicity or carcinogenicity in the drug you’re trying to get approved?
- Time needed for tests?

A
  • You need to Test it in 2 different species

Acute Toxicity - (2 diff. routes)
Sub-Acute Toxicity - (1-3 months of dosing)
Chronic Toxicity - (more than 6 months of dosing)
Carcinogenicity - (2 years)

Mutagenicity - done with an Ames test in a rat (so I guess only one species needed)

20
Q

How long does the FDA have to review paperwork for a drug once its sent in?

A

30 days

aka IRB application approval

21
Q

When is the only time you’ll see sick patients in a Phase I clinical trial?

A

If its a cancer drug

*Cancer patients who have failed other treatments may are allowed to enter these trials

22
Q

Phase I clinical Trial:

  • Purpose?
  • People used?
  • Size?
A

Purpose:
- Find the Minimum Toxic Dose

People Used:
- Healthy adult volunteers

Size:
- Small 10-15 adults (or 20-100 according to his chart)

23
Q

Phase II clinical Trials:

  • Purpose?
  • Dosing?
  • People used?
  • Size?
A

Purpose:
- See if it fixes the illness in humans, Try to figure out dosing and pharacokinetics in humans

Dosing:
- START at the Minimum Toxic Dose from the First trial

People Used:
- People affected by the disease of interest

Size:
100-200 patients

**Note if it doesn’t work in the first 14 pts. Statistics say that there is more than a 95% chance that the drug won’t work

24
Q

Phase III clinical Trials:

  • Purpose?
  • Dosing?
  • People Used?
  • Size?
A

Purpose:
- Compare the drug to a placebo and see if it works
- Eliminate any bias
(this stage is make or break, do benefits outweigh risks?)

Size:
1000-6000 pts.

25
Q

Why might a Phase III trial be stopped?

A
  1. Superior Efficacy of the Trial Agent - you don’t want to screw people out of treatment
  2. Increased risk to patients
26
Q

What drugs have historically been susceptible to the placebo effect?

A
  • Antihypertensives

- Psychiatric Drugs

27
Q

T or F: 30-50% of pts. receiving placebo in a trial will improve

A

True, so drug must have an effect greater than the placebo

  • If the trial just looked at effect being greater than existing agent, there would be no way to determine how much of the effect that due to the placebo

FDA therefore requires new vs. old. vs. placebo

28
Q

What 4 documents are submitted to the FDA for review for drug approval?

A
  • Drug Safety in Animals and humans
  • Evaluation of Carcinogenic Status
  • Evaluation of Teratogenic Status
  • Drug Stability
29
Q

What are the 3 responses the FDA may give to a drug application?

A

Approve, Approvable, Disapprove

Approvable - means gather more information

30
Q

What is pharmacometrics?

- purpose?

A
  • Simultaneous Qualitative Understanding of Drug dose or Exposure and Response (pharmacodynamics)

***Extrapolates info from clinical trials to more scenarios without need for additional phase III trials

  • Applied to lead/support the final approval and labeling related decisions
31
Q

What is the use of data obtained from Pharmacometrics?

A
  • Evidence of Effectivness
  • Dose Optimization
  • Improvement in future Trial design by gaining insight into causes of Clinical Trial Failure
32
Q

What is needed to make a generic drug?

A
  • Only need to show Bioequivlence
33
Q

How do you demonstrate Bioequivalence for a generic?

A
  • Measure AUC drug levels in 24-36 healthy volunteers

- Compare to brand name

34
Q

When do brand name drugs have to do demonstrate bioequivlence on themselves?

A

When the drug is reformulated

35
Q

What is involved in Phase IV of FDA review?

- how does the FDA collect info in this phase and what is done with this info?

A

Phase IV the drug is on the market and its monitored mainly by the FDA medwatch program so they can get info on adverse events

*FDA can use this info. to pull the drug if necessary

36
Q

What adverse affects would you expect to pick up in phase IV that were not picked up in any of the clinical trial phases of Drug approval?

A

Adverse effects that occur in Less Than 1 in 3,000 to 5,000 ppl.

*b/c this is usually your sample size in a phase III trial

37
Q

Differentiate the data the is collected by the FDA in:
- 15-day Reports

  • Periodic Reports
  • Direct Reports
A

Company Submissions:
15-day Reports -adverse events that were serious and unexpected as well as adverse events form clinical trials that are serious and unexpected and are reasonably associated with the drug

Periodic Reports - all of the other reports not in the Direct or 15-day category (presumably benign and expected side effects)

Public Submissions
Direct - drug reports to the FDA that come straight from PUBLIC

38
Q

What is Active Surveillance?

  • aka?
  • Risks?
A

aka Sentinel Initiative

  • Compiling information on drug days by using automated healthcare databases (no reporting, just looking for trends etc.)

Risks:
- Information may be misinterpreted and False positive correlations may be made

39
Q

For what event type is it easiest to establish a causal relationship; common or rare?

A

Rare events - causal relationships are easy to make because they don’t happen for any other reason (flowers growing out of your head)

Common events - having an MI when your 50-70 could be due to a number of factors. Its hard to just blame the drug

40
Q

What rules were implimented by the Controlled substances Act of 1970?

A
  • States can have MORE stringent controls on drugs but not less
  • All drugs containing a controlled substance must be labeled
  • You must be licensed to Distribute these
41
Q
What is the highest class of drug that can be prescribed?
- examples of drugs in this category.
A

Class II (Class I is just your standard illegal drugs)

Class II examples:

  • Morphine
  • Meperidine
  • Amphetamine
42
Q

T or F: the FDA rejects about 1/5 of the drug names it gets each year before marketing

A

False, it rejects about 1/3 of Drug name submissions

43
Q

What is Pharmacogenomic Labeling?

- is this required by the FDA?

A
  • Tells you the impact the drug will have on a given genotype or phenotype or it if it even matters at all

Pharacogenomic Labeling is required by the FDA in some cases but it recommended in other cases

44
Q

What is unique about Off-Label Prescription writing?

- why don’t drug companies change this?

A

Physicians can prescribe drugs for things other than what they were manufactured to do

  • Drug companies cannot Advertise these positive aspects of the drug unless they run through the clincal trials and all of that
  • Cost outweighs the benefit for companies
45
Q

In Product Claim Drug companies must include:

  • Drug Name (brand and generic)
  • at least one FDA-approved use for the drug
  • Most significant risks of the drug
  • Balanced description of benefits and risks
A

In Product Claim Drug companies must include:

  • Drug Name (brand and generic)
  • at least one FDA-approved use for the drug
  • Most significant risks of the drug
  • Balanced description of benefits and risks
46
Q

Reminder Advertisements

  • give name of drug but not uses
  • Drugs with Blackbox warnings must include those
A

Reminder Advertisements

  • give name of drug but not uses
  • Drugs with Blackbox warnings must include those
47
Q

Top 10 Reasons for Drug Recall

  • Lack of assurance of Sterility
  • Deviations from GMP
  • Sub-Potency
  • Microbial Contamination
  • Chemical Contamination
  • Penicillin cross-contamination
  • Drug Marketed w/o approval
  • Failure to Dissolve Properly
  • Exceeding limits for impurities or degradation
A

Top 10 Reasons for Drug Recall

  • Lack of assurance of Sterility
  • Deviations from GMP
  • Sub-Potency
  • Microbial Contamination
  • Chemical Contamination
  • Penicillin cross-contamination
  • Drug Marketed w/o approval
  • Failure to Dissolve Properly
  • Exceeding limits for impurities or degradation